Altamira Therapeutics Anticipates Reduced Operating Expenses Following Partial Spin-off of ATAG, Plans to Update Financial Guidance with New Developments

Reuters

2025/08/29

Altamira <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Anticipates Reduced Operating Expenses Following Partial Spin-off of ATAG, Plans to Update Financial Guidance with New Developments

Altamira Therapeutics Ltd. has announced that it expects its operating expenses to decrease significantly upon the completion of the planned partial spin-off of its ATAG subsidiary. The company plans to support its operations through its current cash position, proceeds from the sale of ATAG shares to private equity investors, as well as through partnering or divesting legacy assets and providing services for associates. Altamira has stated that it will update its financial guidance as new, material information becomes available, particularly regarding the anticipated partial spin-off of ATAG.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altamira Therapeutics Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1066695) on August 29, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2563014047"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2563014047\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2563014047?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-29 19:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2563014047","market":"fut","top_or_hot":-1,"title":"Altamira Therapeutics Anticipates Reduced Operating Expenses Following Partial Spin-off of ATAG, Plans to Update Financial Guidance with New Developments","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Altamira <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Anticipates Reduced Operating Expenses Following Partial Spin-off of ATAG, Plans to Update Financial Guidance with New Developments\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CYTO\">Altamira Therapeutics Ltd.</a> has announced that it expects its operating expenses to decrease significantly upon the completion of the planned partial spin-off of its ATAG subsidiary. The company plans to support its operations through its current cash position, proceeds from the sale of ATAG shares to private equity investors, as well as through partnering or divesting legacy assets and providing services for associates. Altamira has stated that it will update its financial guidance as new, material information becomes available, particularly regarding the anticipated partial spin-off of ATAG.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/CYTOF\">Altamira Therapeutics Ltd.</a> published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1066695) on August 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Altamira Therapeutics Anticipates Reduced Operating Expenses Following Partial Spin-off of ATAG, Plans to Update Financial Guidance with New Developments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAltamira Therapeutics Anticipates Reduced Operating Expenses Following Partial Spin-off of ATAG, Plans to Update Financial Guidance with New Developments\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-29 19:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Altamira <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Anticipates Reduced Operating Expenses Following Partial Spin-off of ATAG, Plans to Update Financial Guidance with New Developments\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CYTO\">Altamira Therapeutics Ltd.</a> has announced that it expects its operating expenses to decrease significantly upon the completion of the planned partial spin-off of its ATAG subsidiary. The company plans to support its operations through its current cash position, proceeds from the sale of ATAG shares to private equity investors, as well as through partnering or divesting legacy assets and providing services for associates. Altamira has stated that it will update its financial guidance as new, material information becomes available, particularly regarding the anticipated partial spin-off of ATAG.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/CYTOF\">Altamira Therapeutics Ltd.</a> published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1066695) on August 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CYTOF","symbol_name":"Altamira Therapeutics Ltd.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nNDL6NvttB:1","article_id":"2563014047","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2563014047","pubTimestamp":1756467776,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Altamira Therapeutics Anticipates Reduced Operating Expenses Following Partial Spin-off of ATAG, Plans to Update Financial Guidance with New Developments. Altamira Therapeutics Ltd. has announced that it expects its operating expenses to decrease significantly upon the completion of the planned partial spin-off of its ATAG subsidiary. The company plans to support its operations through its current cash position, proceeds from the sale of ATAG shares to private equity investors, as well as through partnering or divesting legacy assets and providing services for associates. Altamira has stated that it will update its financial guidance as new, material information becomes available, particularly regarding the anticipated partial spin-off of ATAG.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not b","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"CYTOF":"Altamira Therapeutics Ltd."},"translate_title":"Altamira Therapeutics预计部分分拆ATAG后运营费用将减少，并计划根据新进展更新财务指引","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CYTOF":0.9},"content_text":"Altamira Therapeutics Anticipates Reduced Operating Expenses Following Partial Spin-off of ATAG, Plans to Update Financial Guidance with New Developments\n    \n\nAltamira Therapeutics Ltd. has announced that it expects its operating expenses to decrease significantly upon the completion of the planned partial spin-off of its ATAG subsidiary. The company plans to support its operations through its current cash position, proceeds from the sale of ATAG shares to private equity investors, as well as through partnering or divesting legacy assets and providing services for associates. Altamira has stated that it will update its financial guidance as new, material information becomes available, particularly regarding the anticipated partial spin-off of ATAG.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altamira Therapeutics Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1066695) on August 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}